ABL001 (Asciminib): Mechanism of Action

ABL001 (Asciminib) MOA:Targeting BCR-ABL1/BCR-ABL1 Signaling Pathway for Chronic Myeloid Leukemia

🎯 check ABL001 (Asciminib) product page

ABL001 (Asciminib) is a potent, allosteric BCR-ABL1 kinase inhibitor. It affects the BCR-ABL signaling pathway by binding to the Abl kinase domain, effectively inhibiting the proliferation of chronic myeloid leukemia cells and overcoming TKI resistance.

Primary Applications and Mechanism of Action